Illumina

Illumina dominates the genomic sequencing market, manufacturing the instruments and consumables that generate approximately 80% of the world's sequencing data, with platforms ranging from benchtop sequencers for clinical diagnostics to high-throughput systems for population-scale genomics studies. The company's engineering challenges span embedded systems for sequencing instrument control, real-time signal processing algorithms that translate raw optical data into base calls, bioinformatics software for secondary and tertiary analysis, and cloud platforms that make genomic data accessible to researchers and clinicians. Their recent NovaSeq X series represents a significant technical investment in optics, chemistry, and computational efficiency to drive sequencing costs toward the $100 genome. Illumina's hiring patterns reflect the genomics industry's shift toward clinical applications and cloud-based analysis, with growing emphasis on software engineers and data scientists alongside the traditional optics, chemistry, and hardware engineering disciplines.